Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
38.079,70 +117,90 (+0,31%) EUR/USD
1,0647 -0,0027 (-0,26%) Bitcoin EUR
59.512,28 +2.153,68 (+3,75%) CMC Crypto 200
885,54 0,00 (0,00%)
Amarin Corporation plc (AMRN)
Dopo ore:
| Chiusura precedente | 0,9171 |
| Aperto | 0,9600 |
| Denaro | 0,8799 x 100 |
| Lettera | 0,9258 x 200 |
| Min-Max giorno | 0,8708 - 0,9600 |
| Intervallo di 52 settimane | 0,6500 - 1,4900 |
| Volume | |
| Media Volume | 1.762.146 |
| Capitalizzazione | 349,901M |
| Beta (5 anni mensile) | 2,01 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1500 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,08 |
GlobeNewswireAmarin to Present at the 2023 Cantor Global Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference. 2023 Cantor Global Healthcare Conference (Sept 26 – 28th, 2023; NYC) Date/Time: Tuesday, Sep 26 at 9:55-10:25 AM ET in Track 1 Webcast: https://wsw.com/webcast/cantor19/amrn/2092398 The conference audio will be
- GlobeNewswire
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
– Dutch Ministry of Health Approves VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease – – Italy’s AIFA Pricing & Reimbursement Committee (CPR) Issues Negative Decision on VAZKEPA; Follows Positive Scientific Assessment by the Italian Scientific Technical Committee (CTS) – DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced p
- GlobeNewswire
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel -- DUBLIN, Ireland, BRIDGEWATER, N.J and PETAH TIKVA, ISRAEL, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Isr
